On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data from the Phase 3 MOVe-OUT trial evaluating LAGEVRIO (molnupiravir), an investigational oral antiviral medicine, in non-hospitalized adults with mild to moderate COVID-19 who were at high risk for progressing to severe disease.

Analyses of pre-specified exploratory endpoints indicate that a lower proportion of LAGEVRIO-treated participants in the modified intent-to-treat (MITT) population had an acute care visit or a COVID-19-related acute care visit versus placebo-treated participants in the MITT population.